Reata Pharmaceuticals raised a $25 million Series E funding to advance a pipeline of products through clinical trials. Existing investors Cardinal Investment and Novo A/S led the round. It is thought that Reata has now raised a total of US$66 million.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.